



**The International Council for Harmonisation of Technical Requirements for  
Pharmaceuticals for Human Use**

**ICH E2B(R3) Implementation Working Group  
Electronic Transmission of Individual Case Safety Reports (ICSRs)**

**Questions & Answers**

Version 1.10  
June 16, 2016

---

## Document Change History

Version Number	Date	Description
1.00	12/11/2014	Approved by Steering Committee (Q&A 1-27)
1.10	16/6/2016	Approved by Assembly (Q&A 23, 28-38)

This Q&A document provides clarifications for the harmonized interpretation of the E2B(R3) IG package and should be reviewed in conjunction with the IG package. This will facilitate the implementation of the electronic transmission of Individual Case Safety Reports (ICSRs) in the ICH regions.

Pharmaceutical companies, regulators and vendors were encouraged to submit implementation-related questions to the ICH E2B(R3) IWG; answers to these questions were developed by the ICH E2B(R3) IWG in accordance with the ICH consensus process.

Questions concerning the time frame and specific regional requirements not communicated in the E2B(R3) guidance are answered in guidance documents published for each region.

Future update to this Q&A document, if any, will be published at ICH web site.

E2B(R3) Questions and Answers					
Date of Approval		Document	E2B (R3) data element	Questions	Answers
E2B(R3) IWG0001	November 10, 2014	IG ver 5.01	N/A	<p>Does ICH data type “AN” accept Space?</p> <p>Does ICH data type “AN” accept all characters listed in UTF8?</p>	<p>In principle, ICH “AN” data type accepts all characters, including space and some special characters listed in UTF8, but some characters such as &gt; and &lt; are not allowed with XML message. So please refer to section 3.6 of the ICH ICSR Implementation Guide for further clarification.</p> <p>However, ICH data elements with the ICH “AN” data type may not always have an one-to-one mapping with the data type in ISO/HL7 27953-2 ICSR message standard. The representation of the data can vary across implementations.</p> <p>For Example ICH F.r.4 Normal Low Value and ICH F.r.5 Normal high Value. These data elements specify use of the ICH AN data type; however, the ISO/HL7 27953-2 message specification restricts allowable XML schema values using the HL7 xsi:type code designation Physical Quantity (PQ). The HL7 PQ data type is expressed as two XML schema attributes: value and unit; value has HL7 REAL data type and units are expressed as UCUM codes. For the use and information of the HL7 data type, please refer to the ISO/HL7 27953-2 Informative Annex F: <i>HL7 Data Type Specification</i>.</p> <p>In the Business Rule section for the related data elements, the ICH ICSR Implementation Guide provides information and examples for representing the ICH AN data type with HL7 data type in transmission.</p>

E2B(R3) Questions and Answers					
Date of Approval		Document	E2B (R3) data element	Questions	Answers
E2B(R3) IWG0002	November 10, 2014	IG ver 5.01	N/A	<p>Is it possible to use NI even if NI is not listed in allowed values?                      Because, the explanation of NI is that No information whatsoever can be inferred from this exceptional value. This is the most general exceptional value. It is also the default exceptional value.</p>	<p>No, only nullFlavors specified for each element in IG and Q&amp;A document are acceptable.                      The value set of nullFlavor in Q&amp;A supersede the value set stated in the IG.</p>

E2B(R3) Questions and Answers					
Date of Approval		Document	E2B (R3) data element	Questions	Answers
E2B(R3) IWG0003	November 10, 2014	IG ver 5.01	N/A	The lists of UCUM couldn't be found. Which website should be referred to?	Information about UCUM, including link to download the specification is available at: <a href="http://unitsofmeasure.org/trac/">http://unitsofmeasure.org/trac/</a>

E2B(R3) Questions and Answers					
Date of Approval		Document	E2B (R3) data element	Questions	Answers
E2B(R3) IWG0004	November 10, 2014	IG ver 5.01	N/A	Does XML schema define default values for some attributes?	The ISO/HL7 schema files automatically populate certain attributes with a default value, such as unit='1' for PQ data type and mediaType='text/plain' for ED data type. The ICSR sender should replace the default value with an appropriate value pertaining to the data being transmitted. For example, use the appropriate UCUM code for representing a unit of measurement for physical quantities (PQ) and media designation for encapsulated data (ED). To help reduce parsing errors, the sender should omit optional data element tags if there is no information to be transmitted. For example, patient age is an optional data element and the sender should omit the entire age observation class if no age value is known.

E2B(R3) Questions and Answers					
Date of Approval		Document	E2B (R3) data element	Questions	Answers
E2B(R3) IWG0005	November 10, 2014	IG ver 5.01	N/A	Is there anything senders should consider in creating XML files for ICSRs?	Senders should refer not only to the ICH Implementation Guide and regional Implementation Guides but also its Appendices such as Reference instances, Technical Information and so on.



E2B(R3) Questions and Answers					
Date of Approval		Document	E2B (R3) data element	Questions	Answers
E2B(R3) IWG0006	November 10, 2014	IG ver 5.01	N/A	When 'Z' was added at the end of time values as described in Appendix II (C) ISO 8601 Compliant XML Examples in the IG ver. 5.01, parse error occurred. Can senders use the representations of date and time such as 199411051315Z, 20090601231105.5Z, 20090601231105Z, 200906012331Z or 2009060123Z?	No, the examples described in Appendix II (C) are inappropriate. 'Z' should not be added at the end of time values. XML Schema defines the Time Zone value as <xs:pattern value="[0-9]{1,8} ([0-9]{9,14} [0-9]{14,14}\.[0-9]+)([+ -][0-9]{1,4})?"/>, and Appendix II (B) Time Zone in the IG states that "The syntax is 'CCYYMMDDHHMMSS.UUUU[+ -ZZzz]' where digits can be omitted from right side to express less precision".

E2B(R3) Questions and Answers					
Date of Approval		Document	E2B (R3) data element	Questions	Answers
E2B(R3) IWG0007	November 10, 2014	IG ver 5.01	N/A	There is no guidance whether case sensitive form or case insensitive form should be used for codes in the ICH E2B(R3) ICSR messages.	In the ICH E2B(R3) ICSR messages, case sensitive form should be used for codes. Please refer to regional guidance for more information about case sensitivity.

E2B(R3) Questions and Answers					
Date of Approval		Document	E2B (R3) data element	Questions	Answers
E2B(R3) IWG0008	November 10, 2014	IG ver 5.01	N/A	Use of HL7 nullFlavors requires implementation of very specific business rules for parsing – not necessarily as part of ICSR file validation. ICSR file validation is checking appropriate HL7 nullFlavors by data element (datatype). Backend system parsing rules are different because they affect how data is actually displayed / queried in the database: EX: Date fields with a NI value cannot be parsed to a field structured for date/time.	Support for HL7 nullFlavor values, such as MSK (masked), NI (No Information) and UNK (Unknown) may vary across implementation. Systems should be designed to receive process and re-produce a compliant message utilizing nullFlavors as defined in the ICH E2B(R3) IG.

E2B(R3) Questions and Answers																							
Date of Approval		Document	E2B (R3) data element	Questions	Answers																		
E2B(R3) IWG0009	November 11, 2014	IG ver 5.01	N/A	<p>A man started medications before his partner became pregnant. But she has a miscarriage now.</p> <p>a) Is the ADR a miscarriage?</p> <p>b) Is the patient of the report the father or mother?</p> <p>c) Is the route of administration how the father took the medicine?</p>	<p>Following are abbreviated answer for the question and examples for various scenario regarding parent and/or child/foetus.</p> <p>a) Yes. In this case the ADR should be the miscarriage experienced by the mother.</p> <p>b) The patient should be the mother.</p> <p>c) Yes. The route of administration should be how the father was given the suspect medication.</p> <p><b>Scenario 1: Miscarriage, drug administered to Mother</b></p> <table border="1"> <tr> <td>Patient (D)</td> <td>Mother</td> </tr> <tr> <td>AE (E)</td> <td>Miscarriage</td> </tr> <tr> <td>Drug section (G)</td> <td>Product taken by mother</td> </tr> <tr> <td>Route of Administration (G.k.4.r.10)</td> <td>Route administered to mother</td> </tr> </table> <p><b>Scenario 2: Miscarriage, drug administered to Father</b></p> <table border="1"> <tr> <td>Patient (D)</td> <td>Mother</td> </tr> <tr> <td>AE (E)</td> <td>Miscarriage</td> </tr> <tr> <td>Drug section (G)</td> <td>Product taken by father</td> </tr> <tr> <td>Route of Administration (G.k.4.r.10)</td> <td>Use nullFlavor “UNK” in <b>G.k.4.r.10.1</b> Describe information about father and mother in the narrative</td> </tr> <tr> <td>Additional Information on Drug (G.k.10.r)</td> <td>3 (Drug taken by the father)</td> </tr> </table>	Patient (D)	Mother	AE (E)	Miscarriage	Drug section (G)	Product taken by mother	Route of Administration (G.k.4.r.10)	Route administered to mother	Patient (D)	Mother	AE (E)	Miscarriage	Drug section (G)	Product taken by father	Route of Administration (G.k.4.r.10)	Use nullFlavor “UNK” in <b>G.k.4.r.10.1</b> Describe information about father and mother in the narrative	Additional Information on Drug (G.k.10.r)	3 (Drug taken by the father)
Patient (D)	Mother																						
AE (E)	Miscarriage																						
Drug section (G)	Product taken by mother																						
Route of Administration (G.k.4.r.10)	Route administered to mother																						
Patient (D)	Mother																						
AE (E)	Miscarriage																						
Drug section (G)	Product taken by father																						
Route of Administration (G.k.4.r.10)	Use nullFlavor “UNK” in <b>G.k.4.r.10.1</b> Describe information about father and mother in the narrative																						
Additional Information on Drug (G.k.10.r)	3 (Drug taken by the father)																						

E2B(R3) Questions and Answers																	
Date of Approval		Document	E2B (R3) data element	Questions	Answers												
					<p><b>Scenario 3: foetus or breast-feeding infant is exposed to drug(s) through the mother <i>and</i> experienced adverse events/reactions</b></p> <table border="1"> <tr> <td>Patient (D)</td> <td>Infant/foetus</td> </tr> <tr> <td>AE (E)</td> <td>AE experienced by Infant/foetus</td> </tr> <tr> <td>Drug section (G)</td> <td>Product taken by mother</td> </tr> <tr> <td>Route of Administration (G.k.4.r.10)</td> <td>This is usually an indirect exposure, such as transmammary</td> </tr> <tr> <td>Parent Route of Administration (G.k.4.r.11)</td> <td>Route administered to mother</td> </tr> <tr> <td>For a Parent-child / Foetus Report, Information Concerning the Parent (D.10)</td> <td>Mother's information according to the user guidance for section D</td> </tr> </table>	Patient (D)	Infant/foetus	AE (E)	AE experienced by Infant/foetus	Drug section (G)	Product taken by mother	Route of Administration (G.k.4.r.10)	This is usually an indirect exposure, such as transmammary	Parent Route of Administration (G.k.4.r.11)	Route administered to mother	For a Parent-child / Foetus Report, Information Concerning the Parent (D.10)	Mother's information according to the user guidance for section D
Patient (D)	Infant/foetus																
AE (E)	AE experienced by Infant/foetus																
Drug section (G)	Product taken by mother																
Route of Administration (G.k.4.r.10)	This is usually an indirect exposure, such as transmammary																
Parent Route of Administration (G.k.4.r.11)	Route administered to mother																
For a Parent-child / Foetus Report, Information Concerning the Parent (D.10)	Mother's information according to the user guidance for section D																

E2B(R3) Questions and Answers																			
Date of Approval		Document	E2B (R3) data element	Questions	Answers														
					<p><b>Scenario 4: child/foetus experienced adverse events/reactions through drug(s) administered to father</b></p> <table border="1"> <tr> <td>Patient (D)</td> <td>Child/foetus</td> </tr> <tr> <td>AE (E)</td> <td>AE experienced by child/foetus</td> </tr> <tr> <td>Drug section (G)</td> <td>Product taken by father</td> </tr> <tr> <td>Route of admin (G.k.4.r.10)</td> <td>Use nullFlavor “UNK” in <b>G.k.4.r.10.1</b> Describe information about father and mother in the narrative</td> </tr> <tr> <td>Parent Route of Administration (G.k.4.r.11)</td> <td>Route administered to father</td> </tr> <tr> <td>Additional Information on Drug (G.k.10.r)</td> <td>3 (Drug taken by the father)</td> </tr> <tr> <td>For a Parent-child / Foetus Report, Information Concerning the Parent (D.10)</td> <td>Father’s information according to the user guidance for section D</td> </tr> </table>	Patient (D)	Child/foetus	AE (E)	AE experienced by child/foetus	Drug section (G)	Product taken by father	Route of admin (G.k.4.r.10)	Use nullFlavor “UNK” in <b>G.k.4.r.10.1</b> Describe information about father and mother in the narrative	Parent Route of Administration (G.k.4.r.11)	Route administered to father	Additional Information on Drug (G.k.10.r)	3 (Drug taken by the father)	For a Parent-child / Foetus Report, Information Concerning the Parent (D.10)	Father’s information according to the user guidance for section D
Patient (D)	Child/foetus																		
AE (E)	AE experienced by child/foetus																		
Drug section (G)	Product taken by father																		
Route of admin (G.k.4.r.10)	Use nullFlavor “UNK” in <b>G.k.4.r.10.1</b> Describe information about father and mother in the narrative																		
Parent Route of Administration (G.k.4.r.11)	Route administered to father																		
Additional Information on Drug (G.k.10.r)	3 (Drug taken by the father)																		
For a Parent-child / Foetus Report, Information Concerning the Parent (D.10)	Father’s information according to the user guidance for section D																		

E2B(R3) Questions and Answers					
Date of Approval		Document	E2B (R3) data element	Questions	Answers
E2B(R3) IWG0010	November 10, 2014	IG ver 5.01	N/A	<p>A serious case was sent electronically by a company to a Regulatory Authority. Meanwhile, due to follow-up information received at the company, this case is now determined to be non-serious.</p> <p>a) Should the company send a new message indicating that the case is now non-serious?</p> <p>b) Should the company send a new message to nullify the case in the Regulatory Authority's database?</p> <p>c) If the case becomes serious again, should the company send a new message with the same safety report identifier?</p>	<p>a) Yes, the company should send a new message, updating the previous report with the new information, indicating that the case is now non-serious.</p> <p>b) No, the company should not send a new message to nullify the case in the Regulatory Authority's database.</p> <p>c) Yes, this would be new information, and a follow-up report would be appropriate utilizing the same safety report identifier.</p>

E2B(R3) Questions and Answers					
Date of Approval		Document	E2B (R3) data element	Questions	Answers
E2B(R3) IWG0011	November 10, 2014	IG ver 5.01	N/A	<p>If a report is forwarded to a company by a Health Authority, should the company consider that:</p> <p>a) the Health Authority's causality assessment is at least "possible"?</p> <p>b) the reporter's causality assessment is also at least "possible"?</p>	<p>a) and b) by definition a spontaneous report contains suspected adverse reactions (i.e., a possible causal relationship is suspected but not established). However, there is no universally accepted definition for "possible" in the scale of causality assessment. It is therefore not possible to provide a precise answer to this question. It is up to the company and receiver to define causality assessment method and classify the case-reports accordingly.</p>



E2B(R3) Questions and Answers					
Date of Approval		Document	E2B (R3) data element	Questions	Answers
E2B(R3) IWG0012	November 10, 2014	IG ver 5.01	N/A	There are several references to M5 Identifiers in the E2B R3 Implementation Guide, please confirm these still apply?	All references to M5 Identifiers in the Implementation Guide and associated technical documents should be replaced with ISO IDMP Terms and Identifiers.

E2B(R3) Questions and Answers					
Date of Approval		Document	E2B (R3) data element	Questions	Answers
E2B(R3) IWG0013	November 10, 2014	IG ver 5.01	C.1.1 and C.2.r.3	<p>It is not assumed that ‘In exceptional cases where the country of the primary source is not available to the sender’ described in User Guidance of C.2.r.3.</p> <p>Is there any case that E.i.9 is used as alternative of Reporter’s Country code?</p>	<p>No, it is not assumed that the country of the primary source is not available to sender and there is not any case that E.i.9 is used as alternative of Reporter’s Country Code.</p> <p>In this context, the description in User Guidance of C.1.1 ‘in exceptional circumstances where the country of primary source is unknown, the country where the reaction occurred (E.i.9) should be used to indicate the country code’ is also inappropriate.</p> <p>A change of E.i.9 never change Sender’s (case) Safety Report Unique Identifiers.</p>

E2B(R3) Questions and Answers					
Date of Approval		Document	E2B (R3) data element	Questions	Answers
E2B(R3) IWG0014	November 10, 2014	IG ver 5.01	C.1.3 and C.2.r	How can I identify the primary source and the reporter qualification when an ICSR is forwarded by Health Authorities with minimal or no information on the primary source?	If no information on the primary source is available, section C.2.r should identify the Health Authority as the primary source. Field C.2.r.4 'Qualification' should be populated with nullFlavor "UNK". Additionally, field C.1.3 'Type of report' may be populated with a code of "4" (Not available to sender (unknown), if appropriate).

E2B(R3) Questions and Answers					
Date of Approval		Document	E2B (R3) data element	Questions	Answers
E2B(R3) IWG0015	November 10, 2014	IG ver 5.01	C.1.5	The conformance of C.1.5 is "Required". Even if a sender has only first received information and no follow-up information, must a sender enter date in this field?	Yes, a sender must enter date. If a sender has only first received information, the date of first received information and the date of most recent information are same, so a sender enter the date correspond to C.1.4 in C.1.5.

E2B(R3) Questions and Answers					
Date of Approval		Document	E2B (R3) data element	Questions	Answers
E2B(R3) IWG0016	November 10, 2014	IG ver 5.01	C.2.r.3	<p>The Business Rule(s) of C.2.r.3 Reporter's Country Code in the IG ver. 5.01 states that "When C.2.r.5 is populated '1', nullFlavor is not allowed in this data element unless E.i.9 is populated without a nullFlavor".</p> <p>However nullFlavor is not allowed in E.i.9 Identification of the Country Where the Reaction / Event Occurred. Can senders use nullFlavor in C.2.r.3?</p>	<p>No, the description of Business Rule(s) of C.2.r.3 is inappropriate. E.i.9 only allows a two character country code.</p>

E2B(R3) Questions and Answers					
Date of Approval		Document	E2B (R3) data element	Questions	Answers
E2B(R3) IWG0017	November 10, 2014	IG ver 5.01	D.1	<p>NullFlavor value for D.1 stated in IG ver. 5.01 doesn't match what is stated in Appendix I (B) Backwards and Forwards Compatibility Recommendations (BFC) ver. 2.00. The IG currently states that the nullFlavor value allowed is MSK and the BFC states that the nullFlavor values allowed are MSK, ASKU, NASK and UNK.</p>	<p>The business rule for ICH D.1. Patient (name or initial) concerning the use of allowable null flavor values is incomplete. Senders should refer to table in section 5.6.2 nullFlavour for Fields Required in E2B(R3) and follow guidance concerning use of additional null flavor values for D.1., which include the use of: MSK, ASKU, NASK, UNK value options.</p>

E2B(R3) Questions and Answers					
Date of Approval		Document	E2B (R3) data element	Questions	Answers
E2B(R3) IWG0018	November 10, 2014	IG ver. 5.01 and BFC ver. 2.00	D.7.1.r.3 and D.10.7.1.r.3	<p>Appendix I (B) Backwards and Forwards Compatibility Recommendations (BFC) ver. 2.00 explains that “To upgrade to E2B(R3), ‘Continuing (patient or parent medical history)’ (i.e., B.1.7.1d or B.1.10.7.1d in E2B(R2)) is provided with value ‘3’ (unknown) in E2B(R2), the corresponding field should be provided in E2B(R3) with the null flavour (UNK)”.</p> <p>And the BFC also explains that “To downgrade to E2B(R2), ‘Continuing (patient or parent medical history)’ (i.e., D.7.1.r.3 or D.10.7.1.r.3 in E2B(R3)) has null flavor (UNK) in E2B(R3), the corresponding field in E2B(R2) should be provided with value ‘3’ (unknown)”.</p> <p>However, The IG currently states that the nullFlavor values allowed are MSK, ASK and NASK.</p>	<p>The business rule for D.7.1.r.3 or D.10.7.1.r.3 Continuing concerning the use of allowable null flavor values is incomplete. MSK, ASKU, NASK and UNK are allowed for D.7.1.r.3 and D.10.7.1.r.3.</p> <p>Senders should follow the guidance of upgrading to E2B(R3) or downgrading to E2B(R2) in section 5.6.3 Null Flavour for Optional Codes and Dates concerning use of the null flavour UNK for D.7.1.r.3 or D.10.7.1.r.3.</p> <p>This correction is reflected in the BFC version 2.01 (modified in November 2014).</p>

E2B(R3) Questions and Answers					
Date of Approval		Document	E2B (R3) data element	Questions	Answers
E2B(R3) IWG0019	November 10, 2014	IG ver 5.01	E.i.3.2	<p>About E2B(R3) data element: E.i.3.2 Seriousness Criteria at Event Level,</p> <p>a) How to describe “unknown” and “not serious”? What is allowed value for this data element?</p> <p>b) How to describe allowed values and "left blank" in XML?</p>	<p>a) E.i.3.2 are mandatory elements and False is not a value allowed for this data element. This mandatory data element should either be ‘true’ or nullFlavor= ‘NI’. When the information is unknown or the event is not serious, “NI” should be populated.</p> <p>b) “Left blank” if not serious using the null flavor “NI”. All 6 criteria in E.i.3.2 should be included in XML every time (even if a report is non serious). The following is an XML example. &lt;value xsi:type="BL" nullFlavor="NI" /&gt;</p>



E2B(R3) Questions and Answers							
Date of Approval		Document	E2B (R3) data element	Questions			Answers
E2B(R3) IWG0020	November 10, 2014	IG ver 5.01	E.i.4 and E.i.5	Here is scenario on E.i.4 and E.i.5:			Senders should populate the most accurate information known for each event. A blank field for start date or end date or both is acceptable if the information is not known to the sender. When a precise date is not available, the decision of whether to leave blank or an inferred date for a given event should be left up to the sender's clinical judgment. If the events are thought to be related (i.e., if event1 is a sign or symptom of event2), it would be clinically reasonable to use the earliest start date or latest end date, as relevant, for both events. However, a sender should not infer dates unless there is a clear clinical rationale and this rationale should be stated in the case narrative.
				Reaction Sequence	E.i.4 Start date	E.i.5 End date	
				Reaction 1	01-Feb-2010	02-Feb-2010	
				Reaction 2	03-Feb-2010	-	
				Reaction 3	-	01-Jan-2010	
How to get the blank start date and end date details. As per the IG, if we have to consider start date of first reaction and end date of last reaction, the output will not be correct.							

E2B(R3) Questions and Answers					
Date of Approval		Document	E2B (R3) data element	Questions	Answers
E2B(R3) IWG0021	November 10, 2014	IG ver 5.01	F.r.3.1	Test Result (code): ICH document states – “Optional, but required if F.r.2 is populated, and F.r.3.2 and F.r.3.4 is not populated”. Whereas, EU implementation guide says – “Mandatory if F.r.2.2b is populated, and F.r.3.2 or F.r.3.4 is not populated.”. Similar discrepancy exists for F.r.3.2 and F.r.3.4. The explicit meaning of “OR” / “AND” used in this needs to be clarified.	The conformance of F.r.3.1 is clarified as follows.  Optional, but required if F.r.2 is populated, and neither F.r.3.2 nor F.r.3.4 is populated”.

E2B(R3) Questions and Answers					
Date of Approval		Document	E2B (R3) data element	Questions	Answers
E2B(R3) IWG0022	November 10, 2014	IG ver 5.01	F.r.3.2	How are the NullFlavors 'NINF' and 'PINF' implemented in ICH E2B(R3)?	<p>When empty data elements are transmitted, NullFlavors are used to <i>code</i> the reason for the lack of data in a standardized manner. This allows for the creation of valid messages containing mandatory elements without transmitting content.</p> <p>For ICH E2B(R3), the NullFlavors '<b>NINF</b>' (negative infinity of numbers) and '<b>PINF</b>' (positive infinity of numbers) are used only for the data element ICH E2B(R3) <b>F.r.3.2 Test Result</b>, and only when the element describes a range (e.g. data type IVL&lt;...&gt;) with an (unknown) infinity. For example, the concept of 'equal or greater to 3' can be represented as the range from '3' to 'positive infinity', e.g. <i>any</i> (unknown) number greater than 3.</p>

E2B(R3) Questions and Answers					
Date of Approval		Document	E2B (R3) data element	Questions	Answers
E2B(R3) IWG0023	November 10, 2014; June 16, 2016	IG ver 5.01	F.r.3.2	<p>User Guidance of F.r.3.2 Test Result (value/qualifier) in the IG ver. 5.01 states that “A qualifier symbol can be added to the value when appropriate. The supported qualifiers are ‘greater than’, ‘less than’, ‘greater than or equal to’ and ‘less than or equal to’”. However allowed values are Numeric and null flavor (NINF and PINF). Can senders add a qualifier symbol (&lt;, &gt;, ≤, ≥)?</p>	<p>No, senders cannot add a qualifier symbol in this data element. The example in the business rule section of F.r.3.2 is incorrect and should be ignored.</p> <p>This data element captures the value (amount) for the test result. In ICSR message, this data element is represented in HL7 IVL_PQ data type which is a composite data type with multiple attributes. “Positive Infinity (PINF)” and “Negative Infinity (NINF)” null flavors are used to express “Greater than” and “Less than” a specific value respectively. Followings are examples for test results with exact value, greater or less than a specific value.</p> <p>Test Result = 10 (mg/dl)                      &lt;value xsi:type="IVL PQ"&gt; &lt;center value="10" unit="mg/dl"/&gt;</p> <p>Test Result &lt; 10 (mg/dl)                      &lt;value xsi:type="IVL PQ"&gt; &lt;low nullFlavor="NINF"/&gt;&lt;high value="10" unit="mg/dl" inclusive="false"/&gt;&lt;/value&gt;</p> <p>Test Result &lt;= 10 (mg/dl)                      &lt;value xsi:type="IVL PQ"&gt; &lt;low nullFlavor="NINF"/&gt;&lt;high value="10" unit="mg/dl" inclusive="true"/&gt;&lt;/value&gt;</p> <p>Test Result &gt; 10 (mg/dl)                      &lt;value xsi:type="IVL PQ"&gt; &lt;low value="10" unit="mg/dl" inclusive="false"/&gt;&lt;high nullFlavor="PINF"/&gt;&lt;/value&gt;</p> <p>Test Result &gt;= 10 (mg/dl)                      &lt;value xsi:type="IVL PQ"&gt; &lt;low value="10" unit="mg/dl"</p>

E2B(R3) Questions and Answers					
Date of Approval		Document	E2B (R3) data element	Questions	Answers
					inclusive="true"/><high nullFlavor="PINF"/></value>

E2B(R3) Questions and Answers					
Date of Approval		Document	E2B (R3) data element	Questions	Answers
E2B(R3) IWG0024	November 10, 2014	IG ver 5.01	F.r.3.3	If a value of test results does not have a suitable UCUM code or a unit (for example International Normalized Ratio, INR) or a unit of test results is unknown, how should the test results be entered?	In such case, senders should enter the value and unit as unstructured data in F.r.3.4.

E2B(R3) Questions and Answers					
Date of Approval		Document	E2B (R3) data element	Questions	Answers
E2B(R3) IWG0025	November 10, 2014	IG ver 5.01	G.k.7.r.1 and G.k.7.r.2b	The E2B IG implies the free text field G.k.7.r.1 is optional, however the business rules for G.k.7.r.2b. implies the use of a nullFlavor is mandatory.	The free text 'Not specified' or 'Unknown' should be expressed by using nullFlavor.

E2B(R3) Questions and Answers					
Date of Approval		Document	E2B (R3) data element	Questions	Answers
E2B(R3) IWG0026	November 11, 2014	IG ver 5.01	G.k.8	<p>a) How should re-administration data be entered after recovery from AE, e.g., G.k.4.r.8 or G.k.4.r repetition?</p> <p>b) When multiple dosage information (G.k.4.r) is available for a drug, which dosage information should be used for G.k.8?</p> <p>c) Is it possible to identify the re-administration after drug is discontinued or after drug is temporarily stopped?</p>	<p>Answers to question a) through c) are summarized into the scenarios below:</p> <p>The data element (G.k.8) is not a repeatable data element and captures the action taken with the <i>suspect</i> drug as a result of the reaction(s) / event(s) as provided by the reporter of the information. This data element is a within the ‘parent’ instance of <b>G.k Drug</b> and only one action can be captured for each instance of <b>G.k Drug</b>.</p> <p>Because this data element is not associated with its own ‘time’ element, the relevant ‘time’ for <b>G.k.8 Action(s) Taken with Drug</b> is the onset of the reaction. Analysis of the dosage information records in G.k.4 in combination with start date of the reaction/event in <b>E.i.4 – Date of Start of the Reaction/Event</b> – would enable the receiver of the information to determine the relevant <b>G.k.4 Dosage Information</b> record associated with the reaction(s)/event(s).</p> <p>The information related to the outcome of the reaction(s)/event(s) is noted in <b>E.i.7 - Outcome of Reaction / Event at the Time of Last Observation</b>. If the reaction(s)/event(s) do not recur after reintroducing the drug, <b>G.k.9.i.4 Did Reaction Recur on Re-administration?</b> would be set to 2 (rechallenge was done, reaction did not recur) and <b>E.i.7 – Outcome of Reaction / Event at the Time of Last Observation</b> would be set to 1 = recovered/resolved.</p> <p>An example is provided in Appendix A.</p>



E2B(R3) Questions and Answers					
Date of Approval		Document	E2B (R3) data element	Questions	Answers
E2B(R3) IWG0027	November 10, 2014	IG ver 5.01	G.k.10.r	Clarification was requested for usage on coding reports of possible counterfeit drugs.	"1" should be selected for both suspected and confirmed counterfeit products in G.k.10.r and the appropriate MedDRA term should be selected for E.i.2.1b. Any explanatory information should be included in case narrative. If new information is received to confirm the product is not a counterfeit, then G.k.10.r should be changed appropriately as follow up. If the product is confirmed as a counterfeit, the sender should use the appropriate MedDRA code in H.3.r and explain in narrative.

E2B(R3) Questions and Answers					
Date of Approval		Document	E2B (R3) data element	Questions	Answers
E2B(R3) IWG0028	June 16, 2016	IG ver 5.01	N/A	In the ISO 639-2 language code list some languages appear twice with two different codes designated B and T: for instance Czech is either cze (B) or ces (T) where 'B' indicates 'bibliographic' and 'T' indicates 'terminology'. In such instances is one of these correct (meaning that the other is incorrect) – if so, which, or is either OK?	For those languages where (T) and (B) codes are provided the (T) code should be used in E2B(R3) messages.

E2B(R3) Questions and Answers					
Date of Approval		Document	E2B (R3) data element	Questions	Answers
E2B(R3) IWG0029	June 16, 2016	IG ver 5.01	N/A	Does data length provided in the IG (e.g. 5AN) represent data length (byte) or apparent number of characters? In UTF-8, surrogate pairs and combining characters have longer data length (byte) than their apparent data length.	Data length provided in the IG represents the apparent number of characters. Please note some languages/characters require more than a single byte for a character.

E2B(R3) Questions and Answers					
Date of Approval		Document	E2B (R3) data element	Questions	Answers
E2B(R3) IWG0030	June 16, 2016	IG ver 5.01	C.2.r.5	When retransmitting an ICSR received from another sender such as a regulatory authority, partner company, or other source, which reporter should be marked as 'Primary Source for Regulatory Purposes' (field C.2.r.5)?	As mentioned in the E2B(R3) implementation guide, the primary source of the information is the person who provided the facts about the ICSR. In case of multiple sources, the 'Primary Source for Regulatory Purposes' (C.2.r.5) is the person who first reported the facts to the original sender, not retransmitter. The primary source should be distinguished from senders and retransmitters. Information on the sender and retransmitters is captured in section C.3. When retransmitting an electronic ICSR received from another sender, such as a regulatory authority, partner company, or other source in E2B format, the Primary Source information in the initial transmission should reflect the reporter with first-hand information on the case and this should not be changed. The reporter identified as 'Primary Source for Regulatory Purposes' in the original transmission should remain unchanged in all subsequent retransmission of the case.

E2B(R3) Questions and Answers					
Date of Approval		Document	E2B (R3) data element	Questions	Answers
E2B(R3) IWG0031	June 16, 2016	IG ver 5.01	D.8.r.1	The conformance of D.8.r.1 Name of Drug as Reported is “Required” and the business rule states that “Nullflavor=NA” should be used when there is no previous exposure to a drug or vaccine and no other nullFlavor is allowed. Drug or vaccine exposure history may be unknown in most cases, but nullflavor=UNK is not allowed in this field. How should sender report such cases?	The conformance of D.8.r.1 in the current Implementation Guide is inappropriate. D.8.r Relevant Past Drug History can be left blank when no information is obtained. Technically, D.8.r.1 is required by the schema if any data element in section D.8.r is used. Therefore the conformance of D.8.r.1 should be interpreted as Conditionally Required. Null flavor = UNK is allowed when no information is available but need to enter D.8.r.1.

E2B(R3) Questions and Answers					
Date of Approval		Document	E2B (R3) data element	Questions	Answers
E2B(R3) IWG0032	June 16, 2016	IG ver 5.01	F.r.3.4	Which data element (F.r.3.4 Result unstructured data or F.r.6 Comments) is applicable for test results such as comments on CT, MRI, or radiogram?	Field F.r.6 is reserved for comments made by the reporter about the results of tests and procedures. Unstructured findings from tests and procedures such as CT, MRI, radiogram, etc. should be provided as free text in field F.r.3.4.

E2B(R3) Questions and Answers					
Date of Approval		Document	E2B (R3) data element	Questions	Answers
E2B(R3) IWG0033	June 16, 2016	IG ver 5.01	G.k.6	The mother's drug exposure has started prior to her pregnancy. Is "G.k.6 Gestation period at time of exposure" necessary to be populated on the child/foetus report and/or mother report?	It is appropriate to use G.k.6 to capture the earliest exposure during pregnancy, a clinical judgment should be used to choose the most appropriate value/unit.

E2B(R3) Questions and Answers					
Date of Approval		Document	E2B (R3) data element	Questions	Answers
E2B(R3) IWG0034	June 16, 2016	IG ver 5.01	D.2.2.1	Is “D.2.2.1 Gestation Period When Reaction/Event Was Observed in the Foetus” necessary in the foetus report when drug was taken by father?	In a foetus report, regardless the exposure from father or mother, the foetus age information should be provided in D.2.2.1. Information concerning the parent should be provided in section D.10.



E2B(R3) Questions and Answers					
Date of Approval		Document	E2B (R3) data element	Questions	Answers
E2B(R3) IWG0035	June 16, 2016	IG ver 5.01	D.2	What is an appropriate age for newborn if an adverse drug reaction/event has been developed during pregnancy but just observed at time of delivery?	Section D.2 provides several options for reporting patient age information. The sender should select the most appropriate field based on the information provided. Based on the information provided in the question, field D.2.3 may be the most appropriate field to report the patient age.

E2B(R3) Questions and Answers					
Date of Approval		Document	E2B (R3) data element	Questions	Answers
E2B(R3) IWG0036	June 16, 2016	IG ver 5.01	G.k.9.i.4	<p>What is an appropriate value for “G.k.9.i.4 Did reaction recur on re-administration?” if adverse drug reaction/event on re-administration is not exactly the same as the one on previous administration?</p> <p>Ex) E.i.2.1 Reaction/event: liver disorder</p> <p>Re-administration: Aspartate aminotransferase increased</p>	<p>Medical judgment should be used to assess the conceptual similarity of the events. MedDRA codes do not need to be identical. [Refer to MedDRA Points-to-Consider documents.]</p>


E2B(R3) Questions and Answers					
Date of Approval		Document	E2B (R3) data element	Questions	Answers
E2B(R3) IWG0037	June 16, 2016	Reference Instances	N/A	The codesystem versions for the E2B code lists used in the ICH E2B(R3) reference instances are old compared to the latest version of the E2B code lists. Should a sender update the codesystem version appropriately?	Yes, a sender should update the codesystem version in ICSR messages (xml files) for submission. Acceptable codesystem version(s) are designated by regulatory authorities in each region.

E2B(R3) Questions and Answers					
Date of Approval		Document	E2B (R3) data element	Questions	Answers
E2B(R3) IWG0038	June 16, 2016			<p>ISO 3166 Part 1 (alpha-2) country codes are provided in the ISO web site.  <a href="https://www.iso.org/obp/ui/#home">https://www.iso.org/obp/ui/#home</a>                      There are some categories like “Officially assigned codes” or “Other code types”. Does ICH accept “Officially assigned codes” only?                      Note: “EU” is categorized in “exceptionally reserved”</p>	<p>IG specifies use of ISO 3166 Part 1 (alpha-2). ISO 3166 Part 1 (alpha-2) supports use of country codes in E2B(R3) messages. This includes “Officially assigned” country codes plus “EU” in the “Exceptionally reserved” category. The “Unassigned” category should not be used. “Transitionally reserved”, “Indeterminately reserved” and “Formerly used” categories may be used when appropriate, e.g., for legacy data.</p>

**Appendix A**

Example for E2B(R3)IWG0026

Consider a patient starting a drug for smoking cessation. The dose is titrated upwards over 2 weeks. After 4 weeks of use, the patient has onset of nightmares. As a result, the drug is withdrawn and subsequently the reaction/event is resolved.




Parent Element	Parent Value	Child Element	Child Value
C.1.5 Date of Most Recent Information for This Report	February 2 <sup>nd</sup>		
G.k.2 Drug Identification	k=1 'QuitSmoking'		
G.k.8 Action(s) Taken with Drug	k=1 'drug withdrawn'		
		G.k.4.r Dosage and Relevant Information	k=1, r=1 January 1 <sup>st</sup> : 0.5mg daily, orally, x 7 days
			k=1, r=2 January 8 <sup>th</sup> : 1mg daily, orally, x 7 days

			k=1, r=3	January 15 <sup>th</sup> -29 <sup>th</sup> :1mg twice daily, orally (stopped)
		<b>G.k.9.i</b>	i=1	January 29 <sup>th</sup> : onset of (E.i.1) = <i>Nightmares</i> ; (E.i.7=1-Recovered/Resolved)
		<b>Drug-reaction(s) / Event(s) Matrix</b>		

**Follow-up ICSR:**

Subsequently two weeks later, the drug re-introduced (dose, duration and action taken are unknown) and the reaction/event recurred.



Parent Element	Parent Value	Child Element	Child Value
<b>C.1.5 Date of Most Recent Information for This Report</b>	March 15th		
<b>G.k.2 Drug Identification</b>	k=1 'QuitSmoking'		
<b>G.k.8 Action(s) Taken with</b>	k=1 'Unknown'		

Drug				
		<b>G.k.4.r Dosage and Relevant Information</b>	k=1, r=1	January 1 <sup>st</sup> : 0.5mg daily, orally, x 7 days duration
			k=1, r=2	January 8 <sup>th</sup> : 1mg daily, orally, x 7 days duration
			k=1, r=3	January 15 <sup>th</sup> -29 <sup>th</sup> : 1mg twice daily, orally (stopped)
			k=1, r=4	February 13 <sup>th</sup> : unknown, unknown
		<b>G.k.9.i Drug-reaction(s) / Event(s) Matrix</b>	i=1	January 29 <sup>th</sup> : onset of (E.i.1) = <i>Nightmares</i> ; G.k.9.i.4 = 1 yes - yes (rechallenge was done, reaction recurred); (E.i.7=0-Unknown)